Becton, Dickinson and Company (BDX)
| Market Cap | 72.71B |
| Revenue (ttm) | 19.90B |
| Net Income (ttm) | 1.87B |
| Shares Out | 290.82M |
| EPS (ttm) | 6.35 |
| PE Ratio | 39.90 |
| Forward PE | 20.04 |
| Dividend | $3.28 (1.30%) |
| Ex-Dividend Date | Sep 8, 2021 |
| Volume | 928,277 |
| Open | 253.22 |
| Previous Close | 253.82 |
| Day's Range | 252.44 - 254.63 |
| 52-Week Range | 221.69 - 264.69 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 267.80 (+5.8%) |
| Est. Earnings Date | Nov 4, 2021 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; in...
Financial Performance
In 2020, BDX's revenue was $17.12 billion, a decrease of -1.00% compared to the previous year's $17.29 billion. Earnings were $874.00 million, a decrease of -29.17%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for BDX stock is "Buy." The 12-month stock price forecast is 267.80, which is an increase of 5.77% from the latest price.
News
2 Safe Dividend Growth Stocks You Can Buy and Forget About
These yields may seem low, but you'll likely be earning much more on your initial investment over time.
BD Joins the Race to Zero: Largest Alliance Dedicated to Achieving Net Zero Emissions by 2050
FRANKLIN LAKES, N.J., Sept. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, with support from a number of partners including Global ...
BD Partners with Washington State in Back-to-School Testing Effort
FRANKLIN LAKES, N.J., Sept. 21, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been selected by the state of Was...
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
3 Low-Risk Stocks for Conservative Investors
Not every investing strategy has to involve trying to beat the market.
Becton Dickinson CEO on first Covid smartphone test and how it works
Thomas Polen, Becton Dickenson CEO, joins Closing Bell to talk about his company's smartphone Covid test.
Why Biden's Action Plan Is Bullish For COVID-19 Testing Stocks
On Thursday, President Joe Biden revealed his new COVID-19 action plan, which includes $2 billion in government spending on 280 million rapid point of care and at-home COVID-19 tests. On Friday, Bank of...
Notable Becton Dickinson Insider Trades $5.72 Million In Company Stock
James Lim, Executive Vice President at Becton, Dickinson (NYSE:BDX), made a large buy and sell of company shares on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U....
BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency
BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.
BD to Present at Two Upcoming Virtual Healthcare Investor Conferences in September
FRANKLIN LAKES, N.J., Aug. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will present at the fo...
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
BD Locks FDA Emergency Use Nod For At-Home COVID-19 Antigen Test
The FDA has issued an Emergency Use Authorization (EUA) for Becton Dickinson and Co's (NYSE: BDX) BD Veritor At-Home COVID-19 Test. Also Read: BD's Automated Molecular Diagnostics Platform Wins FDA Ap...
BD Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results
FRANKLIN LAKES, N.J., Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration (FD...
BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV
Becton Dickinson and Co (NYSE: BDX) has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human pa...
BD Launches Fully Automated High-Throughput Molecular Diagnostic Platform for U.S. Laboratories
FRANKLIN LAKES, N.J., Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has launched a new, fully automat...
BD Announces Pricing of Tender Offers
FRANKLIN LAKES, N.J., Aug. 19, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announce...
Becton, Dickinson and Company Announces Early Tender Results
FRANKLIN LAKES, N.J., Aug. 19, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers ...
BD's (BDX) New Offering to Boost Labs' Flow Cytometry Abilities
BD's (BDX) latest product offering is expected to help improve access to instrumentation for complex scientific research to more laboratories.
New BD Benchtop Cell Analyzer Enhances Laboratory Access and Accelerates Scientific Research
FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new benchtop cell analyze...
Christopher DelOrefice to Join BD as Chief Financial Officer
FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been name...
BD Announces Upsizing of Tender Offers
FRANKLIN LAKES, N.J., Aug. 10, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has amended its previously announced tender offers to purcha...
JPMorgan Downgrades Becton Dickinson On Muffled FY22 Outlook
JPMorgan downgraded Becton Dickinson and Co (NYSE:BDX) to Neutral from Overweight with a price target of $265, down from $280. While Becton reported better than expected top and bottom-line Q3 results,...
BD (BDX) Beats on Q3 Earnings and Revenues, Ups '21 View
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal third quarter, thus driving up the overall top line.
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt sec...